These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 28947726)

  • 1. [Pericardioversion and catheter ablation use of rivaroxaban in light of X-VERT and VENTURE-AF trials].
    Akıllı R; Demir M
    Turk Kardiyol Dern Ars; 2017 Sep; 45(Suppl 4):15-23. PubMed ID: 28947726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rivaroxaban in atrial fibrillation cardioversion: insights from the X-VeRT trial.
    Farag M; Gorog DA
    Future Cardiol; 2015 Mar; 11(2):147-51. PubMed ID: 25760874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation.
    Renda G; Zimarino M; Ricci F; Piccini JP; Ezekowitz MD; Patel MR; Cappato R; Giugliano RP; De Caterina R
    Am J Med; 2016 Oct; 129(10):1117-1123.e2. PubMed ID: 27262782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meta-analysis of risk of stroke and thrombo-embolism with rivaroxaban versus vitamin K antagonists in ablation and cardioversion of atrial fibrillation.
    Nairooz R; Sardar P; Pino M; Aronow WS; Sewani A; Mukherjee D; Paydak H; Maskoun W
    Int J Cardiol; 2015; 187():345-53. PubMed ID: 25839640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contemporary Management of Direct Oral Anticoagulants During Cardioversion and Ablation for Nonvalvular Atrial Fibrillation.
    Trujillo TC; Dobesh PP; Crossley GH; Finks SW
    Pharmacotherapy; 2019 Jan; 39(1):94-108. PubMed ID: 30548542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Periprocedural Management of New Oral Anticoagulants in Atrial Fibrillation Ablation.
    Zak M; Castiblanco SA; Garg J; Palaniswamy C; Jacobs LE
    J Cardiovasc Pharmacol Ther; 2015 Sep; 20(5):457-64. PubMed ID: 25827857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Network meta-analysis of efficacy and safety of competitive oral anticoagulants in patients undergoing radiofrequency catheter ablation of atrial fibrillation.
    Li PJ; Xiao J; Yang Q; Feng Y; Wang T; Liu GJ; Liang ZA
    J Interv Card Electrophysiol; 2016 Sep; 46(3):213-24. PubMed ID: 27001171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial.
    Piccini JP; Stevens SR; Lokhnygina Y; Patel MR; Halperin JL; Singer DE; Hankey GJ; Hacke W; Becker RC; Nessel CC; Mahaffey KW; Fox KA; Califf RM; Breithardt G;
    J Am Coll Cardiol; 2013 May; 61(19):1998-2006. PubMed ID: 23500298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation.
    Providência R; Marijon E; Albenque JP; Combes S; Combes N; Jourda F; Hireche H; Morais J; Boveda S
    Europace; 2014 Aug; 16(8):1137-44. PubMed ID: 24550347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of the new target specific oral anticoagulants in the management of anticoagulation for cardioversion and atrial fibrillation ablation.
    Kowalski M; Parikh V
    J Thromb Thrombolysis; 2013 Aug; 36(2):175-86. PubMed ID: 23605999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes after catheter ablation and cardioversion in patients with non-valvular atrial fibrillation: results from the prospective, observational XANTUS study.
    Camm AJ; Turpie AGG; Hess S; Amarenco P; Lambelet M; Haas S; van Eickels M; Kirchhof P;
    Europace; 2018 Jun; 20(6):e87-e95. PubMed ID: 29016755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-reported treatment satisfaction and budget impact with rivaroxaban vs. standard therapy in elective cardioversion of atrial fibrillation: a post hoc analysis of the X-VeRT trial.
    Hohnloser SH; Cappato R; Ezekowitz MD; Evers T; Sahin K; Kirchhof P; Meng IL; van Eickels M; Camm AJ;
    Europace; 2016 Feb; 18(2):184-90. PubMed ID: 26487668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rivaroxaban vs. Warfarin for Anticoagulation in Patients with Atrial Fibrillation Undergoing Ablation and Cardioversion.
    Hawks MK; Bryce C
    Am Fam Physician; 2016 Oct; 94(7):Online. PubMed ID: 27929207
    [No Abstract]   [Full Text] [Related]  

  • 14. Influence of periprocedural anticoagulation strategies on complication rate and hospital stay in patients undergoing catheter ablation for persistent atrial fibrillation.
    Gunawardene M; Willems S; Schäffer B; Moser J; Akbulak RÖ; Jularic M; Eickholt C; Nührich J; Meyer C; Kuklik P; Sehner S; Czerner V; Hoffmann BA
    Clin Res Cardiol; 2017 Jan; 106(1):38-48. PubMed ID: 27435077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delaying cardioversion following 4-week anticoagulation in case of persistent atrial fibrillation after a transcatheter ablation procedure to reduce silent cerebral thromboembolism: a single-center pilot study.
    Pianelli M; Scaglione M; Anselmino M; Caponi D; Garcia P; Cesarani F; Toso E; Raimondo C; Halimi F; Leclercq JF; Gaita F
    J Cardiovasc Med (Hagerstown); 2011 Nov; 12(11):785-9. PubMed ID: 21941200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry.
    Lakkireddy D; Reddy YM; Di Biase L; Vallakati A; Mansour MC; Santangeli P; Gangireddy S; Swarup V; Chalhoub F; Atkins D; Bommana S; Verma A; Sanchez JE; Burkhardt JD; Barrett CD; Baheiry S; Ruskin J; Reddy V; Natale A
    J Am Coll Cardiol; 2014 Mar; 63(10):982-8. PubMed ID: 24412445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-Analysis of Efficacy and Safety of New Oral Anticoagulants Compared With Uninterrupted Vitamin K Antagonists in Patients Undergoing Catheter Ablation for Atrial Fibrillation.
    Wu S; Yang YM; Zhu J; Wan HB; Wang J; Zhang H; Shao XH
    Am J Cardiol; 2016 Mar; 117(6):926-34. PubMed ID: 26803384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contemporary approach to electrical and pharmacological cardioversion of atrial fibrillation.
    Rajagopalan B; Curtis AB
    Postgrad Med; 2012 Nov; 124(6):26-35. PubMed ID: 23322136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of outcomes after cardioversion or atrial fibrillation ablation in patients with differing periprocedural anticoagulation regimens.
    Kochhäuser S; Khaykin Y; Beardsall J; Juta R; Hache P; Trought K; Lenton-Brym T; Tsang B; Pantano A; Beardsall M; Wulffhart Z; Verma A
    Can J Cardiol; 2014 Dec; 30(12):1541-6. PubMed ID: 25475459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Atrila fibrillation: a review].
    Brunckhorst CB; Holzmeister J; Scharf Ch; Binggeli Ch; Hellermann JP; Duru F
    Praxis (Bern 1994); 2004 May; 93(19):803-15. PubMed ID: 15185487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.